Abstract:
Summary. Second generation generic of Cyclosporine A, Equoral®, showed a significant interpatient variation of the active substance concentration in the stable patients with kidney transplant. In the same time its variation in each single patient was minimal. These data corresponds to the pharmaceutical profile as well as concentrations/ AUC in patients treated with original Cyclosporine A. We have registered no clinical or laboratory adverse effects of the evaluated medication.
Description:
Centrul Dializă şi Transplant Renal IMSP Spitalul Clinic Republican, Catedra Urologie şi Nefrologie Chirurgicală USMF “N. Testemiţanu”, Al V-lea Congres de Urologie, Dializă şi Transplant Renal din Republica Moldova cu participare internaţională (1-13 iunie 2011)
